Is PAIN IN EXTREMITY a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed PAIN IN EXTREMITY.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 93 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported PAIN IN EXTREMITY to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and PAIN IN EXTREMITY. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause PAIN IN EXTREMITY, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes PAIN IN EXTREMITY. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if PAIN IN EXTREMITY ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing PAIN IN EXTREMITY: 93
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where PAIN IN EXTREMITY is a reported side effect: 2.7936%

FDA reports of any drug causing PAIN IN EXTREMITY : 75735
Average percentage for all medicated patients where PAIN IN EXTREMITY is reported as a complication: 0.4747%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with PAIN IN EXTREMITY:

FOSAMAX (9975 patients)
ASPIRIN (6516 patients)
FORTEO (6434 patients)
VIOXX (5574 patients)
ENBREL (5395 patients)
LIPITOR (5303 patients)
HUMIRA (4627 patients)
TYSABRI (3811 patients)
AVONEX (3233 patients)
PREDNISONE (3055 patients)
SYNTHROID (2979 patients)
CRESTOR (2937 patients)
LYRICA (2884 patients)
NEXIUM (2821 patients)
NEURONTIN (2749 patients)
ZOMETA (2739 patients)
METHOTREXATE (2725 patients)
SEROQUEL (2705 patients)
LISINOPRIL (2547 patients)
LEVAQUIN (2421 patients)
COUMADIN (2410 patients)
LASIX (2334 patients)
CELEBREX (2233 patients)
YAZ (2101 patients)
ZOCOR (2070 patients)
VITAMIN D (2056 patients)
ATENOLOL (2042 patients)
OMEPRAZOLE (2028 patients)
SIMVASTATIN (2025 patients)
FOLIC ACID (2023 patients)
PLAVIX (1999 patients)
PRILOSEC (1989 patients)
YASMIN (1902 patients)
XANAX (1898 patients)
HYDROCHLOROTHIAZIDE (1832 patients)
AMBIEN (1792 patients)
CALCIUM (1770 patients)
IBUPROFEN (1758 patients)
NORVASC (1748 patients)
MAGNEVIST (1669 patients)
OXYCONTIN (1648 patients)
LEVOTHYROXINE SODIUM (1587 patients)
FUROSEMIDE (1586 patients)
ZOLOFT (1581 patients)
TOPROL-XL (1571 patients)
AREDIA (1528 patients)
VICODIN (1528 patients)
CYMBALTA (1527 patients)
BONIVA (1515 patients)
GABAPENTIN (1498 patients)
SANDOSTATIN LAR (1468 patients)
PROTONIX (1465 patients)
PERCOCET (1456 patients)
ALBUTEROL (1402 patients)
ACETAMINOPHEN (1397 patients)
ALENDRONATE SODIUM (1351 patients)
PREVACID (1337 patients)
LEXAPRO (1316 patients)
PREMARIN (1293 patients)
NEXAVAR (1288 patients)
REMICADE (1283 patients)
POTASSIUM CHLORIDE (1231 patients)
METFORMIN HCL (1200 patients)
LORAZEPAM (1191 patients)
PREDNISONE TAB (1188 patients)
ATIVAN (1181 patients)
DIOVAN (1177 patients)
DIGOXIN (1140 patients)
PAXIL (1110 patients)
ACTONEL (1097 patients)
SINGULAIR (1095 patients)
FOSAMAX PLUS D (1056 patients)
LANTUS (1048 patients)
CLONAZEPAM (1046 patients)
HEPARIN SODIUM INJECTION (1040 patients)
ZETIA (1026 patients)
ADVAIR DISKUS 100/50 (1024 patients)
WARFARIN SODIUM (994 patients)
LORTAB (992 patients)
MULTI-VITAMINS (989 patients)
METOPROLOL TARTRATE (988 patients)
OMNISCAN (987 patients)
OXYCODONE HCL (979 patients)
ALLOPURINOL (975 patients)
REBIF (973 patients)
PROZAC (965 patients)
DURAGESIC-100 (951 patients)
FLEXERIL (933 patients)
ASCORBIC ACID (919 patients)
MULTI-VITAMIN (919 patients)
ZYRTEC (904 patients)
CALCIUM CARBONATE (903 patients)
CIPROFLOXACIN (897 patients)
WELLBUTRIN (866 patients)
DEXAMETHASONE (850 patients)
ARIMIDEX (846 patients)
KLONOPIN (833 patients)
MORPHINE (832 patients)
EFFEXOR (826 patients)
FISH OIL (822 patients)
CHANTIX (806 patients)
ALPRAZOLAM (804 patients)
AMLODIPINE (800 patients)
AVELOX (791 patients)
NIASPAN (791 patients)
VALIUM (790 patients)
BENADRYL (787 patients)
RECLAST (786 patients)
VITAMIN E (776 patients)
SPIRIVA (773 patients)
BACLOFEN (772 patients)
ZANTAC (768 patients)
TRAMADOL HCL (762 patients)
NITROGLYCERIN (760 patients)
METOPROLOL (755 patients)
CELEXA (749 patients)
BETASERON (744 patients)
ALLEGRA (743 patients)
DECADRON (741 patients)
NAPROXEN (732 patients)
INSULIN (732 patients)
PREDNISOLONE (719 patients)
ZOFRAN (711 patients)
BYETTA (702 patients)
DIAZEPAM (694 patients)
COREG (692 patients)
CALCIUM (UNSPECIFIED) (681 patients)
LOVENOX (675 patients)
TRAZODONE HCL (659 patients)
COZAAR (658 patients)
GLUCOPHAGE (655 patients)
AMOXICILLIN (650 patients)
VITAMINS (UNSPECIFIED) (641 patients)
MOTRIN (640 patients)
REVLIMID (638 patients)
AVANDIA (636 patients)
VITAMIN B-12 (636 patients)
SOLIRIS (634 patients)
ZITHROMAX (626 patients)
DILAUDID (625 patients)
TYLENOL (CAPLET) (620 patients)
ULTRAM (614 patients)
TYLENOL (609 patients)
LEVOXYL (607 patients)
ELAVIL (602 patients)
CIPRO (601 patients)
CLONIDINE (597 patients)
METFORMIN (595 patients)
FENTANYL (594 patients)
AMITRIPTYLINE HCL (594 patients)
HYDROCODONE (587 patients)
PRAVACHOL (586 patients)
ACCUTANE (584 patients)
CEPHALEXIN (582 patients)
EVISTA (580 patients)
TOPAMAX (580 patients)
MORPHINE SULFATE (573 patients)
HYDROCODONE BITARTRATE (565 patients)
VYTORIN (560 patients)
SPIRONOLACTONE (560 patients)
EPOGEN (556 patients)
FLONASE (556 patients)
ACTOS (554 patients)
ALTACE (547 patients)
LOPRESSOR (544 patients)
SOMA (544 patients)
RAMIPRIL (541 patients)
RISPERDAL (541 patients)
PROLIA (538 patients)
ARANESP (536 patients)
PLAQUENIL (527 patients)
ZYPREXA (519 patients)
COLACE (516 patients)
REGLAN (516 patients)
TRICOR (510 patients)
BEXTRA (508 patients)
XELODA (505 patients)
EFFEXOR XR (501 patients)
POTASSIUM (500 patients)
GLIPIZIDE (499 patients)
CLARITIN (498 patients)
FEMARA (498 patients)
HUMALOG (498 patients)
VELCADE (497 patients)
PEPCID (495 patients)
OPTIMARK (492 patients)
GLYBURIDE (489 patients)
PROCRIT (489 patients)
[THERAPY UNSPECIFIED] (476 patients)
ACIPHEX (476 patients)
TAMOXIFEN CITRATE (475 patients)
MOBIC (473 patients)
MIRALAX (463 patients)
EXJADE (463 patients)
METOPROLOL SUCCINATE (462 patients)
TEMAZEPAM (458 patients)
PRAVASTATIN (458 patients)
RANITIDINE (457 patients)
CHEMOTHERAPEUTICS NOS (451 patients)
PANTOPRAZOLE (451 patients)
TAXOTERE (450 patients)
FLUCONAZOLE (450 patients)
KEFLEX (449 patients)
FLOMAX (448 patients)
GLEEVEC (445 patients)
NUVARING (443 patients)
ENALAPRIL MALEATE (443 patients)
PROMETHAZINE (441 patients)
IRON (440 patients)
SKELAXIN (439 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about PAIN IN EXTREMITY and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.